← Back to Search

Monoclonal Antibodies

Skyrizi for Psoriasis

Phase 4

Recruiting

Led By Jaehwan Kim, MD, PhD

Research Sponsored by Jaehwan Kim

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

More than 10% body surface area has plaque psoriasis involvement.

Adult males or females with a diagnosis of plaque psoriasis for at least 6 months.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 52

Awards & highlights

Study Summary

This trial is testing a new drug, Skyrizi, to see if it produces long-term disease clearance in psoriasis patients.

Who is the study for?

Adults with plaque psoriasis for at least 6 months, a PASI score over 12, and more than 10% body surface area affected. Participants must not use other psoriasis treatments or live vaccines during the trial and cannot be pregnant.Check my eligibility

What is being tested?

The study tests Risankizumab's ability to maintain long-term remission in psoriasis patients. It involves comparing skin biopsies before and after treatment to understand immune changes correlating with disease progression.See study design

What are the potential side effects?

Potential side effects of Risankizumab may include reactions at the injection site, increased risk of infections due to immune system suppression, headaches, fatigue, and possible gastrointestinal issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

Over 10% of my body is covered by plaque psoriasis.

Select...

I have been diagnosed with plaque psoriasis for at least 6 months.

Select...

I agree not to use other psoriasis treatments, live vaccines, or become pregnant during the trial.

Select...

Over 10% of my body is covered by psoriasis plaques.

Select...

I agree not to use other psoriasis treatments, live vaccines, or become pregnant during the trial.

Select...

I have been diagnosed with plaque psoriasis for at least 6 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 52

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 52

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determination of regulatory immune cell changes induced by risankizumab

Secondary outcome measures

Validation of predictive models that anticipate disease recurrence after risankizumab treatment

Trial Design

1Treatment groups

Experimental Treatment

Group I: Psoriasis treatment with risankizumabExperimental Treatment3 Interventions

Moderate-to-severe psoriasis treatment with risankizumab for 16 weeks

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH

484 Previous Clinical Trials

1,086,987 Total Patients Enrolled

9 Trials studying Psoriasis

1,292 Patients Enrolled for Psoriasis

AbbVieIndustry Sponsor

958 Previous Clinical Trials

502,375 Total Patients Enrolled

62 Trials studying Psoriasis

125,592 Patients Enrolled for Psoriasis

Jaehwan KimLead Sponsor

Media Library

Risankizumab-Rzaa (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04630652 — Phase 4

Psoriasis Research Study Groups: Psoriasis treatment with risankizumab

Psoriasis Clinical Trial 2023: Risankizumab-Rzaa Highlights & Side Effects. Trial Name: NCT04630652 — Phase 4

Risankizumab-Rzaa (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04630652 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the aggregate amount of participants engaging in this clinical research?

"Affirmative. A review of the clinicaltrials.gov listing confirms that this medical investigation is actively seeking participants and was first advertised on April 7th 2021. The study hopes to enroll 20 individuals from one specific location."

Answered by AI

Can you provide an assessment of the potential perils associated with Risankizumab-Rzaa?

"Data gathered by our team at Power suggests that the safety of Risankizumab-Rzaa is highly likely, and it was awarded a score of 3. This drug has been approved for use in Phase 4 trials."

Answered by AI

Are any new participants eligible to join this investigation?

"According to the clinicaltrials.gov platform, this trial is currently open for enrollment and started recruiting on April 7th 2021 with its last update being November 30th 2022."

Answered by AI

For what medical conditions is Risankizumab-Rzaa primarily prescribed?

"Risankizumab-Rzaa is an effective remedy for dental plaque, psoriasis and skin disinfection therapy."

Answered by AI

Are there any extant studies on the efficacy of Risankizumab-Rzaa?

"At present, there are 30 trials in progress for Risankizumab-Rzaa with 15 of them being Phase 3 experiments. Although Gdansk, Pomorskie is the primary area running clinical studies on this medication, it can be accessed at a total of 3222 different sites around the globe."

Answered by AI